AESOP

A Safer Tomorrow: AESOP Technology's Battle Against Look-Alike, Sound-Alike Medication Errors

Retrieved on: 
Monday, October 23, 2023
Name, Documentation, Medical error, Hope, Physician, Approximation error, AESOP, AI, Patient, Patient safety, SAN, Fatigue, Nursing, Medical device

SAN FRANCISCO, Oct. 23, 2023 /PRNewswire/ -- Medication errors are a critical problem in healthcare, and Look-Alike, Sound-Alike (LASA) medication errors pose a particularly daunting challenge.

Key Points: 
  • SAN FRANCISCO, Oct. 23, 2023 /PRNewswire/ -- Medication errors are a critical problem in healthcare, and Look-Alike, Sound-Alike (LASA) medication errors pose a particularly daunting challenge.
  • Studies show that LASA errors account for approximately one in four medication errors, making them a significant threat to patients.
  • AESOP Technology is thus pleased to announce remarkable results from its recent clinical research , demonstrating its exceptional effectiveness in preventing LASA errors.
  • More than half of all medication errors occur during the prescription phase, making it a critical focus for improving patient safety.

SOAP Health and AESOP Technology Unite to Provide Advanced AI Solutions for Clinical Decision-Support and Medical Coding

Retrieved on: 
Thursday, September 7, 2023
AESOP, Natural language processing, Partnership, Natural language, SOAP, Health, Data collection, MBA, Documentation, Data analysis, MD, Patient, Physician, Risk, Diagnosis, AI, CPO, Safety, Medical device

BOCA RATON, Fla., Sept. 7, 2023 /PRNewswire/ -- SOAP Health and AESOP Technology are excited to announce a transformative partnership that will push the boundaries of AI-enhanced medical encounters. This collaboration combines AESOP's cutting-edge DxPrime and DeepDRG solutions with SOAP Health's patented and clinically validated Ideal Medical AI Assistant™ to fuse patient-reported data with Electronic Medical Record Systems (EMRs) data to create Precision Patient Profiles™ that give physicians the most comprehensive view and understanding of their patients to improve speed to diagnosis, workflow efficiency, and revenue.

Key Points: 
  • BOCA RATON, Fla., Sept. 7, 2023 /PRNewswire/ -- SOAP Health and AESOP Technology are excited to announce a transformative partnership that will push the boundaries of AI-enhanced medical encounters.
  • Steven Charlap, MD, MBA, CEO of SOAP Health, believes this alliance marks a milestone in effectively integrating AI into clinical encounters.
  • "The joint venture between AESOP Technology and SOAP Health promises to radically optimize physician data collection and medical coding," says Jeremiah Scholl, Co-founder and CPO of AESOP Technology.
  • For more details on how SOAP Health and AESOP Technology are collaborating, please visit the SOAP Health Partner Page at www.soap.health/aesop

Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Thursday, May 11, 2023
AESOP, SBRT, HNC, Priority review, Otorhinolaryngology, Esophagitis, University, ARNP, Therapy, File, MSN, Oncology Nursing Society, Pharming, LAPC, Head, Survival, New Drug Application, NDA, Cancer, Lung cancer, Market access, MBA, NSCLC, Mucositis, Radiation therapy, Neck, Marketing, Sale, ASCO, SOM, Congress, Incidence, Literature, Data analysis, American Society of Clinical Oncology, Patient, Investment, Annual general meeting, PDUFA, ONS, Research, FDA, Galera, Letter, CKD, Chemoradiotherapy, Food, Society, Pharmaceutical industry, Nursing

MALVERN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2023, and provided recent corporate updates.

Key Points: 
  • With Priority Review designation, the Prescription Drug User Fee Act (PDUFA) target date assigned by the FDA for the NDA is August 9, 2023.
  • Research and development expenses were $7.3 million in the first quarter of 2023, compared to $8.1 million for the same period in 2022.
  • As of March 31, 2023, Galera had cash, cash equivalents and short-term investments of $47.8 million.
  • Galera expects that its existing cash, cash equivalents and short-term investments will enable Galera to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.

Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates

Retrieved on: 
Wednesday, March 8, 2023
Sale, PDUFA, New Drug Application, Literature, HNC, AESOP, NSCLC, Investment, Letter, GPC, SOM, FDA, NDA, Therapy, Chemoradiotherapy, University, Radiation therapy, SBRT, Survival, Cancer, Research, Incidence, Priority review, Mucositis, Head, Patient, File, Esophagitis, MD, Food, LAPC, Lung cancer, Pharmaceutical industry, Medical imaging, Cryptocurrency

MALVERN, Pa., March 08, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the fourth quarter and year ended December 31, 2022 and provided recent corporate updates.

Key Points: 
  • On February 15, 2023, the Company announced that the FDA accepted for filing and granted priority review to the NDA for avasopasem.
  • Research and development expenses were $8.1 million in the fourth quarter of 2022, compared to $9.2 million for the same period in 2021.
  • General and administrative expenses were $5.0 million in the fourth quarter of 2022, compared to $5.3 million for the same period in 2021.
  • As of December 31, 2022, Galera had cash, cash equivalents and short-term investments of $31.6 million.

Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

Retrieved on: 
Wednesday, November 9, 2022
CKD, LAPC, Research, Meta-analysis, Therapy, Radiation therapy, Survival, Chemoradiotherapy, GC4419, Ownership, Radiation, Review, Thomas Jefferson University, Pancreatic cancer, Annual general meeting, Food, Literature, Society, Incidence, American Society for Radiation Oncology, SEC, Compte rendu, U.S. Securities and Exchange Commission, Cancer, Chronic kidney disease, Patient, CEO, NSCLC, Mucositis, COVID-19, Private Securities Litigation Reform Act, Esophagitis, SBRT, Nasdaq, Johns Hopkins, AESOP, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SOM, Privacy, Physician, Manganese, NDA, Cisplatin, FDA, GLOBE, Head, Health, Pancreas, Investment, ASTRO, Lung cancer, Large-cell lung carcinoma, Annual report, Failure, Safety, U.S. FDA, Pharmaceutical industry, Medical imaging, Air cargo, Company

MALVERN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.

Key Points: 
  • The meta-analysis of the already positive results from both the ROMAN and GT-201 trials underscores that avasopasem improves SOM across these measures.
  • Research and development expenses were $8.1 million in the third quarter of 2022, compared to $14.8 million for the same period in 2021.
  • General and administrative expenses were $4.9 million in the third quarter of 2022, compared to $5.5 million for the same period in 2021.
  • As of September 30, 2022, Galera had cash, cash equivalents and short-term investments of $42.8 million.

Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

Retrieved on: 
Wednesday, October 26, 2022
Therapy, Meta-analysis, Society, Cancer, Nasdaq, Mucositis, EGFR, Annual general meeting, Patient, IMRT, Large-cell lung carcinoma, SOM, Cisplatin, AESOP, Chronic kidney disease, Radiation therapy, GLOBE, CKD, NDA, American Society for Radiation Oncology, Incidence, ASTRO, Pharmaceutical industry

MALVERN, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the presentation of one-year tumor and renal function outcomes data from its Phase 3 ROMAN trial of avasopasem manganese 90 mg for radiotherapy-induced severe oral mucositis (SOM), as well as topline results from a recently completed meta-analysis of the ROMAN and GT-201 SOM trial results, at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting. Final data from its Phase 2 AESOP trial of avasopasem for radiotherapy-induced esophagitis were also presented today in a separate session. In addition, poster presentations during ASTRO highlighted the completed Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer. The presentations and posters are currently available in the ASTRO digital program.

Key Points: 
  • Final data from its Phase 2 AESOP trial of avasopasem for radiotherapy-induced esophagitis were also presented today in a separate session.
  • CKD (eGFR
  • The prospective exploration of this potential benefit of avasopasem was driven by published preclinical data and a post hoc assessment of patients from the GT-201 trial presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Approximately 42,000 patients with head and neck cancer undergo standard-of-care radiotherapy every year in the U.S. and are at risk of experiencing SOM.

Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

Retrieved on: 
Monday, September 26, 2022
SBRT, Therapy, Health, Safety, COVID-19, Otorhinolaryngology, Mucositis, Peripheral, NSCLC, GC4419, LAPC, Privacy, Early Stage, Annual general meeting, Pancreatic cancer, Society, Chemoradiotherapy, American Society for Radiation Oncology, Neoplasm, Cancer, Ownership, 2021 Essex County Council election, CDT, Annual report, Nasdaq, Private Securities Litigation Reform Act, ASTRO, AESOP, Radiation therapy, Large-cell lung carcinoma, SOM, GLOBE, SEC, Failure, Central neurogenic hyperventilation, Pharmaceutical industry, Patient

Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.

Key Points: 
  • Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.
  • Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer.
  • Galeras selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

AI Startup AESOP Raises $3M to Tackle Medical and Billing Errors

Retrieved on: 
Wednesday, August 31, 2022
Mayo Clinic, Information system, TMU, Technology, Digital, SAN, Insurance, International Medical Informatics Association, Solution, Decision-making, Glaucoma, Physician, Taipei Medical University, Diagnosis, CIO, Hospital, Medical school, Approximation error, Yu-Chuan Jack Li, Big data, Harvard University, Medicine, Capital University of Medical Sciences, AI, Altitude, Medical device, Acetazolamide, AESOP, Paracetamol

SAN FRANCISCO, Aug. 31, 2022 /PRNewswire/ -- Digital health startup AESOP Technology has raised a $2.95 million series pre-A round to address the growing medical and billing errors problem.

Key Points: 
  • SAN FRANCISCO, Aug. 31, 2022 /PRNewswire/ -- Digital health startup AESOP Technology has raised a $2.95 million series pre-A round to address the growing medical and billing errors problem.
  • Originally from Taiwan, AESOP started as a universityspin-off from Taipei Medical University (TMU).Professor Yu Chuan (Jack)Li, the founder and current president of the International Medical Informatics Association,spent tenyears before AESOP working on big data approaches to reduce medication errors.
  • He initially applied the model to launch a product, RxPrime (previously known asMedGuard), that identifies wrong-drug errors.
  • They worked together to broaden the types of errors the AI could identify and on products they could use to improve the US healthcare system.

AESOP Technology Wins Coveted Place in Mayo Clinic Platform_Accelerate Program to Build Better AI Model for Healthcare

Retrieved on: 
Monday, August 22, 2022
Health care, Mayo Clinic, Machine learning, International Classification of Diseases, Patient safety, CEO, Technology, Program, SAN, Insurance, Solution, Workload, Medicine, Knowledge Organization (journal), Diagnosis, AESOP, Prescription, CPO, Industry, ICD, Growth, Patient, Medical device

SAN FRANCISCO, Aug. 22, 2022 /PRNewswire/ -- AESOP Technology announced that they have been accepted into Mayo Clinic Platform_Accelerate , a 20-week program that helps early-stage health tech AI startups get market-ready.

Key Points: 
  • SAN FRANCISCO, Aug. 22, 2022 /PRNewswire/ -- AESOP Technology announced that they have been accepted into Mayo Clinic Platform_Accelerate , a 20-week program that helps early-stage health tech AI startups get market-ready.
  • How AI can support them gains more importance," says Jim Long, the CEO of AESOP Technology.
  • As part of the program, Mayo Clinic will take an equity position in the startup.
  • AESOP aims to optimize the clinical decision support process with more flexible AI-powered technology to improve patient safety and medical coding quality.

Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, August 9, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Survival, ASCO, RECIST, NDA, Literature, Oral Oncology, Lung cancer, CEO, GLOBE, Neoplasm, Failure, Private Securities Litigation Reform Act, SOM, SEC, Cancer, Investment, AESOP, Incidence, Esophagitis, Annual report, NSCLC, Patient, Review, Therapy, COVID-19, LAPC, Chemoradiotherapy, Large-cell lung carcinoma, Pancreatic cancer, Society, Safety, U.S. FDA, Research, ISOO, SBRT, Privacy, Head, Ownership, GC4419, Wastewater treatment, Nasdaq, Food, Health, Pharmaceutical industry, Tutoring, Company

MALVERN, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the second quarter ended June 30, 2022 and provided recent corporate updates.

Key Points: 
  • An oral presentation on Phase 3 ROMAN data of avasopasem for SOM was given at the 2022 ASCO Annual Meeting.
  • Research and development expenses were $6.7 million in the second quarter of 2022, compared to $16.0 million for the same period in 2021.
  • General and administrative expenses were $5.3 million in the second quarter of 2022, broadly consistent with the second quarter of 2021.
  • As of June 30, 2022, Galera had cash, cash equivalents and short-term investments of $52.0 million.